McLean Estelle, Renju Jenny, Wamoyi Joyce, Bukenya Dominic, Ddaaki William, Church Kathryn, Zaba Basia, Wringe Alison
Malawi Epidemiology and Intervention Research Unit, Karonga, Malawi.
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Sex Transm Infect. 2017 Jul;93(Suppl 3). doi: 10.1136/sextrans-2016-052972.
To explore what influences on engagement with Option B+ in four sub-Saharan African settings.
In-depth interviews were conducted in 2015, with 22 HIV-positive women who had been pregnant since Option B+ was available, and 15 healthcare workers (HCWs) involved in HIV service delivery. Participants were purposely selected from four health and demographic surveillance sites in Malawi, Tanzania and Uganda. A thematic content analysis was conducted to investigate what influenced engagement with Option B+.
Feeling 'ready' was key to pregnant women accepting antiretroviral treatment (ART) on the same day as diagnosis at antenatal clinic; this was influenced by previous knowledge of HIV-positive status, interactions with HCWs and relationship with their partners. The desire to protect their unborn infant was the main issue that motivated women to initiate treatment, temporarily over-riding barriers to starting ART. Many HCWs recognised that pressurising women into starting ART may lead them to stop treatment following delivery. However, their own responsibility to protect the infant sometimes drove HCWs to use strong persuasive techniques to initiate pregnant women onto ART as early as possible, occasionally causing women to disengage.
Protecting the baby superseded feelings of unpreparedness for lifelong ART and may explain poor retention observed in Option B+ programmes. Women may benefit from more time to accept their status, and counselling on the long-term value of ART beyond the pregnancy and breastfeeding period. Strategies to promote readiness for same-day initiation of lifelong treatment are urgently needed, and may provide important lessons for universal test-and-treat implementation.
探讨撒哈拉以南非洲四个地区对采用B+方案治疗的参与度有哪些影响因素。
2015年开展了深入访谈,对象包括22名自B+方案实施以来怀孕的艾滋病毒呈阳性女性,以及15名参与艾滋病毒服务提供的医护人员。参与者是从马拉维、坦桑尼亚和乌干达的四个健康与人口监测点中特意挑选出来的。开展了主题内容分析,以调查影响采用B+方案治疗的因素。
感觉“做好准备”是孕妇在产前诊所确诊当天接受抗逆转录病毒治疗(ART)的关键;这受到先前对艾滋病毒呈阳性状态的了解、与医护人员的互动以及与伴侣关系的影响。保护未出生婴儿的愿望是促使女性开始治疗的主要因素,暂时克服了开始接受抗逆转录病毒治疗的障碍。许多医护人员认识到,向女性施压开始抗逆转录病毒治疗可能会导致她们在分娩后停止治疗。然而,他们自身保护婴儿的责任有时促使医护人员使用强有力的劝说技巧,尽早让孕妇开始接受抗逆转录病毒治疗,偶尔会导致女性不再参与。
保护婴儿的需求取代了对终身抗逆转录病毒治疗准备不足的担忧,这可能解释了B+方案中观察到的留存率低的现象。女性可能会从更多时间来接受自身状况以及关于抗逆转录病毒治疗在孕期和哺乳期之后的长期价值的咨询中受益。迫切需要制定促进当日开始终身治疗准备就绪的策略,这可能为普遍检测和治疗的实施提供重要经验教训。